[1]
|
Hansen, J.M., Coleman, R.L. and Sood, A.K. (1990) Targeting the Tumour Microenvironment in Ovarian Cancer. Euro-pean Journal of Cancer, 56, 131-143. https://doi.org/10.1016/j.ejca.2015.12.016
|
[2]
|
杨瑞红, 王丽敏, 赵惠. 上皮性卵巢癌并发深静脉血栓的相关影响因素分析[J]. 实用癌症杂志, 2022, 37(12): 2077-2080.
|
[3]
|
Xia, L., Wang, Y., Cai, S. and Xu, M. (2021) DGAT1 Expression Promotes Ovarian Cancer Progression and Is Associated with Poor Prognosis. Journal of Immunology Research, 2021, Article ID: 6636791.
https://doi.org/10.1155/2021/6636791
|
[4]
|
Lane, E.R., Hsu, E.K. and Murray, K.F. (2015) Management of Ascites in Children. Expert Review of Gastroenterology & Hepatology, 9, 1281-1292. https://doi.org/10.1586/17474124.2015.1083419
|
[5]
|
李庆. 卵巢癌腹水形成的分子机制及治疗进展[J]. 系统医学, 2019, 4(22): 192-195.
|
[6]
|
周术卫, 牟晓玲. 卵巢癌腹水对肿瘤影响的研究进展[J]. 实用妇科内分泌电子杂志, 2019, 6(14): 23-24, 26.
|
[7]
|
Piché, A. (2018) Malignant Peritoneal Effusion Acting as a Tumor Environment in Ovarian Cancer Progression: Impact and Significance. World Journal of Clinical Oncology, 9, 167-171. https://doi.org/10.5306/wjco.v9.i8.167
|
[8]
|
Krugmann, J., Schwarz, C.L., Melcher, B., et al. (2019) Malignant As-cites Occurs Most Often in Patients with High-Grade Serous Papillary Ovarian Cancer at Initial Diagnosis: A Retrospec-tive Analysis of 191 Women Treated at Bayreuth Hospital, 2006-2015. Archives of Gynecology and Obstetrics, 299, 515-523.
https://doi.org/10.1007/s00404-018-4952-9
|
[9]
|
张媛媛, 周萍, 程静新, 袁建林. 腹水细胞学检查对卵巢恶性肿瘤的诊断价值[J]. 新疆医科大学学报, 2010, 33(8): 957-960.
|
[10]
|
毛柳. 卵巢癌腹水及外周血CD4+CD25+Treg/CD4+T细胞含量及其意义分析[J]. 中国妇幼保健, 2016, 31(22): 4871-4874.
|
[11]
|
Chudecka-Głaz, A.M., Cymbaluk-Płoska, A.A., Menkiszak, J.L., et al. (2015) Assessment of Selected Cytokines, Proteins, and Growth Factors in the Peritoneal Fluid of Patients with Ovarian Cancer and Benign Gynecological Conditions. OncoTargets and Therapy, 8, 471-85. https://doi.org/10.2147/OTT.S73438
|
[12]
|
Bansal, A., Srinivasan, R., Rohilla, M., et al. (2020) Morphologic and Immunocytochemical Features of High-Grade Serous Carcinoma of Ovary in Ascitic Fluid Effusion and Fine-Needle Aspiration Cytology. American Journal of Clinical Pathology, 154, 103-114. https://doi.org/10.1093/ajcp/aqaa028
|
[13]
|
齐冬雪, 张春芳, 张昶, 等. SALL4、CD30、D2-40和glypican-3在卵巢生殖细胞肿瘤中的表达及应用[J]. 诊断病理学杂志, 2017, 24(5): 358-362.
|
[14]
|
李会, 王俊杰. WT1和VEGF在上皮性卵巢癌组织中的表达及临床意义[J]. 中国老年学杂志, 2017, 37(22): 5609- 5610.
|
[15]
|
Szender, J.B., Emmons, T., Belliotti, S., et al. (2017) Impact of Ascites Volume on Clinical Outcomes in Ovarian Cancer: A Cohort Study. Gynecologic Oncology, 146, 491-497. https://doi.org/10.1016/j.ygyno.2017.06.008
|
[16]
|
Lane, D., Matte, I., Garde-Granger, P., Bessette, P. and Piché, A. (2018) Ascites IL-10 Promotes Ovarian Cancer Cell Migration. Cancer Microenvironment, 11, 115-124. https://doi.org/10.1007/s12307-018-0215-3
|
[17]
|
Lane, D., Matte, I., Laplante, C., et al. (2016) CCL18 from Ascites Promotes Ovarian Cancer Cell Migration through Proline-Rich Tyrosine Kinase 2 Signaling. Molecular Cancer, 15, Article No. 58.
https://doi.org/10.1186/s12943-016-0542-2
|
[18]
|
Gawrychowski, K., Szewczyk, G., Skopińska-Różewska, E., et al. (2014) The Angiogenic Activity of Ascites in the Course of Ovarian Cancer as a Marker of Disease Progression. Disease Markers, 2014, Article ID: 683757.
https://doi.org/10.1155/2014/683757
|
[19]
|
盛慧, 陈慧, 潘丽, 李丹. 卵巢癌患者腹水中CD90(+)细胞促进肿瘤细胞腹腔播散[J]. 中国妇幼保健, 2015, 30(24): 4216-4219.
|
[20]
|
Kim, S., Gwak, H., Kim, H.S., et al. (2016) Malig-nant Ascites Enhances Migratory and Invasive Properties of Ovarian Cancer Cells with Membrane Bound IL-6R in Vitro. Oncotarget, 7, 83148-83159.
https://doi.org/10.18632/oncotarget.13074
|
[21]
|
Yousif, N.G. (2014) Fibronectin Promotes Migration and Invasion of Ovarian Cancer Cells through up-Regulation of FAK-PI3K/Akt Pathway. Cell Biology International, 38, 85-91. https://doi.org/10.1002/cbin.10184
|
[22]
|
Nakamura, M., Ono, Y.J., Kanemura, M., et al. (2015) Hepatocyte Growth Factor Secreted by Ovarian Cancer Cells Stimulates Peritoneal Implantation via the Mesothelial-Mesenchymal Transition of the Peritoneum. Gynecologic Oncology, 139, 345-354. https://doi.org/10.1016/j.ygyno.2015.08.010
|
[23]
|
Matte, I., Lane, D., Laplante, C., Garde-Granger, P., Rancourt, C. and Piché, A. (2015) Ovarian Cancer Ascites Enhance the Migration of Patient-Derived Peritoneal Mesothelial Cells via cMet Pathway through HGF-Dependent and -Independent Mechanisms. International Journal of Cancer, 137, 289-298. https://doi.org/10.1002/ijc.29385
|
[24]
|
Mikuła-Pietrasik, J., Uruski, P., Szubert, S., et al. (2016) Biochemical Com-position of Malignant Ascites Determines High Aggressiveness of Undifferentiated Ovarian Tumors. Medical Oncology, 33, Article No. 94.
https://doi.org/10.1007/s12032-016-0810-4
|
[25]
|
Ghoneum, A., Almousa, S., Warren, B., et al. (2021) Exploring the Clinical Value of Tumor Microenvironment in Platinum-Resistant Ovarian Cancer. Seminars in Cancer Biology, 77, 83-98.
https://doi.org/10.1016/j.semcancer.2020.12.024
|
[26]
|
Kim, S., Lee, M., Dhanasekaran, D.N. and Song, Y.S. (2018) Activation of Lxrɑ/β by Cholesterol in Malignant Ascites Promotes Chemoresistance in Ovarian Cancer. BMC Cancer, 18, Article No. 1232.
https://doi.org/10.1186/s12885-018-5152-5
|
[27]
|
Pasquier, J., Gosset, M., Geyl, C., et al. (2018) CCL2/CCL5 Se-creted by the Stroma Induce IL-6/PYK2 Dependent Chemoresistance in Ovarian Cancer. Molecular Cancer, 17, Article No. 47. https://doi.org/10.1186/s12943-018-0787-z
|
[28]
|
Gong, Y., Yang, J., Wang, Y., Xue, L. and Wang, J. (2020) Metabolic Factors Contribute to T-Cell Inhibition in the Ovarian Cancer Ascites. International Journal of Cancer, 147, 1768-1777. https://doi.org/10.1002/ijc.32990
|
[29]
|
Gong, T., Zhang, P., Jia, L. and Pan, Y. (2020) Suppres-sion of Ovarian Cancer by Low-Intensity Ultrasound through Depletion of IL-6/STAT3 Inflammatory Path-way-Maintained Cancer Stemness. Biochemical and Biophysical Research Communications, 526, 820-826. https://doi.org/10.1016/j.bbrc.2020.03.136
|
[30]
|
Khan, A.N.H., Kolomeyevskaya, N., Singel, K.L., et al. (2015) Targeting Myeloid Cells in the Tumor Microenvironment Enhances Vaccine Efficacy in Murine Epithelial Ovarian Cancer. Oncotarget, 6, 11310-11326.
https://doi.org/10.18632/oncotarget.3597
|
[31]
|
Kolomeyevskaya, N.V., Lele, S.B., Miller, A., et al. (2015) Oxali-platin Is a Safe Alternative Option for Patients with Recurrent Gynecologic Cancers after Hypersensitivity Reaction to Carboplatin. International Journal of Gynecologic Cancer, 25, 42-48. https://doi.org/10.1097/IGC.0000000000000307
|
[32]
|
Lane, D., Matte, I., Garde-Granger, P., et al. (2015) Inflam-mation-Regulating Factors in Ascites as Predictive Biomarkers of Drug Resistance and Progression-Free Survival in Se-rous Epithelial Ovarian Cancers. BMC Cancer, 15, Article No. 492. https://doi.org/10.1186/s12885-015-1511-7
|
[33]
|
Huang, H., Li, Y.J., Lan, C.Y., et al. (2013) Clinical Significance of Ascites in Epithelial Ovarian Cancer. Neoplasma, 60, 546-552. https://doi.org/10.4149/neo_2013_071
|
[34]
|
Kolomeyevskaya, N., Eng, K.-H., Khan, A.N.H., et al. (2015) Cyto-kine Profiling of Ascites at Primary Surgery Identifies an Interaction of Tumor Necrosis Factor-α and Interleukin-6 in Predicting Reduced Progression-Free Survival in Epithelial Ovarian Cancer. Gynecologic Oncology, 138, 352-357. https://doi.org/10.1016/j.ygyno.2015.05.009
|
[35]
|
Trifanescu, O.G., Gales, L.N, Tanase, B.C., et al. (2023) Prog-nostic Role of Vascular Endothelial Growth Factor and Correlation with Oxidative Stress Markers in Locally Advanced and Metastatic Ovarian Cancer Patients. Diagnostics, 13, Article No. 166. https://doi.org/10.3390/diagnostics13010166
|
[36]
|
Bekes, I., Friedl, T.W.P., Köhler, T., et al. (2016) Does VEGF Facilitate Local Tumor Growth and Spread into the Abdominal Cavity by Suppressing Endothelial Cell Adhesion, Thus Increasing Vascular Peritoneal Permeability Followed by Ascites Production in Ovarian Cancer? Molecular Cancer, 15, Article No. 13.
https://doi.org/10.1186/s12943-016-0497-3
|
[37]
|
Ferriss, J.S., Java, J.J., Bookman, M.A., et al. (2015) Ascites Predicts Treatment Benefit of Bevacizumab in Front-Line Therapy of Advanced Epithelial Ovarian, Fallopian Tube and Peritoneal Cancers: An NRG Oncology/GOG Study. Gynecologic Oncology, 139, 17-22. https://doi.org/10.1016/j.ygyno.2015.07.103
|
[38]
|
Xu, H., Ma, Y., Zhang, Y., et al. (2016) Identification of Cathep-sin K in the Peritoneal Metastasis of Ovarian Carcinoma Using in-Silico, Gene Expression Analysis. Journal of Cancer, 7, 722-729. https://doi.org/10.7150/jca.14277
|
[39]
|
黄啸, 范建玄, 蔡树模, 等. CK7等单抗在鉴别原发与转移性卵巢癌腹水中的意义[J]. 中国癌症杂志, 2000, 10(6): 35-38.
|
[40]
|
Iwahashi, H., Miyamoto, M., Minabe, S., et al. (2021) Diagnostic Efficacy of Ascites Cell Block for Ovarian Clear Cell Carcinoma. Diagnostic Cytopathology, 49, 735-742. https://doi.org/10.1002/dc.24734
|